Article in The American journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Pamela M MurnaneDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.ORCID 0000-0002-3773-5831
Majid AfsharDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Gabriel ChamieDepartment of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0002-5860-8081
Robert L CookDepartment of Epidemiology, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-7770-3754
Tekeda FergusonComprehensive Alcohol-HIV/AIDS Research Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Lamia Y HaqueDepartment of Internal Medicine (Section of Digestive Diseases) and Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-6650-0978
Karen R JacobsonDepartment of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0003-4239-3685
Amy C JusticeUnited States Department of Veterans Affairs, VA Connecticut Healthcare System, West Haven, Connecticut, USA.ORCID 0000-0003-0139-5502
Theresa W KimDepartment of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0001-6043-0721
Mandana KhaliliDepartment of Medicine, Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0001-9178-9139
Evgeny KrupitskyFirst Pavlov State Medical University, St. Petersburg, Russia.ORCID 0000-0002-0529-4525
Kathleen A McGinnisUnited States Department of Veterans Affairs, VA Connecticut Healthcare System, West Haven, Connecticut, USA.ORCID 0000-0003-4844-3372
Patricia MolinaComprehensive Alcohol-HIV/AIDS Research Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.ORCID 0000-0002-3598-384
Winnie R MuyindikeDepartment of Internal Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID 0000-0002-6694-2645
Bronwyn MyersCurtin EnAble Institute, Faculty of Health Sciences, Curtin University, Perth, Australia.ORCID 0000-0003-0235-6716
Veronica L RichardsTSET Health Promotion Research Center, University of Oklahoma Health Sciences Center, Tulsa, Oklahoma, USA.ORCID 0000-0002-1391-0607
Kaku So-ArmahDepartment of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0003-1505-6384
Scott StewartDepartment of Family Medicine, Division of Addiction Medicine, University at Buffalo, Buffalo, New York, USA.
Mark S SulkowskiDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-2145-6352
Phyllis C TienDepartment of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0003-3867-6770
Judith A HahnDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.ORCID 0000-0002-2697-8264
Funding
Translational Research/Education ComponentP60AA009803 · NIAAA · LSU HEALTH SCIENCES CENTER · PI DAVID A WELSH · 2004 to 2026
$42.6M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Alcohol Associated Outcomes Among HIV+/- Aging VeteransU10AA013566 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2006 to 2010
$12.7M
PREVENTION AND METHODOLOGY TRAINING (PAMT)T32DA017629 · NIDA · PENNSYLVANIA STATE UNIVERSITY-UNIV PARK · PI Eric D Claus, Rina D Eiden · 2005 to 2026
$9.5M
Supplement: CoPARC: Colorado Pulmonary Alcohol Research CollaborativeR24AA019661 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI ELLEN L BURNHAM · 2011 to 2026
$8.5M
Management/Hepatitis C/HIV-infected and Uninfected IDU'sR01DA016065 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2003 to 2018
$8.0M
Alcohol and Multisubstance Use in the Veterans Aging Cohort StudyU01AA020790 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$7.7M
Pharmacotherapy for alcohol consumptionin HIV-infected women: randomized trialU01AA020797 · NIAAA · UNIVERSITY OF FLORIDA · PI COHEN, RONALD A, COOK, ROBERT L · 2011 to 2021
$7.2M
Novel Extensions of Alcohol Contingency Management in People Living with HIVP01AA029543 · NIAAA · UNIVERSITY OF FLORIDA · PI PORGES, ERIC · 2021 to 2025
$6.6M
URBAN ARCH (5/5) Boston Cohort - Alcohol and HIV-associated comorbidity and complications: Frailty, Functional impairment, Falls, and Fractures (the 4F study)U01AA020784 · NIAAA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HEEREN, TIMOTHY C., KIM, THERESA W · 2011 to 2021
$6.4M
The HIV and Alcohol Research center focused on Polypharmacy (HARP)P01AA029545 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2021 to 2025
$6.3M
Sex Disparities in Overall Response to ART Among HIV Infected IndividualsU24AA020794 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
introductionAccurate assessment of alcohol use informs prevention and management of liver disease. We examined whether phosphatidylethanol (PEth, an alcohol metabolite) blood concentrations are associated with liver fibrosis risk independently of self-reported alcohol use, among persons with and without HIV.
methodsWe pooled individual-level data from 12 studies from the United States, Russia, Uganda, and South Africa with PEth, Alcohol Use Disorders Identification Test-Consumption (AUDIT-C), and fibrosis-4 (FIB-4) measurements. We conducted mixed-effects logistic regression of the relationship between PEth and AUDIT-C as continuous variables (after checking linearity), with high FIB-4 (≥2.67). We divided PEth (range 0-1,000) by 83.3 to put it on the same scale as AUDIT-C (0-12) to directly compare odds ratios. Adjusted models included sex, race/ethnicity, age, body mass index, HIV, and virologic suppression status.
resultsAmong 4,644 adults, the median age was 49 years (interquartile range [IQR]: 40-55), 998 (21%) were female, and 3,520 (76%) were living with HIV, among whom 2,386 (68%) were virologically suppressed. Median PEth was 13 ng/mL (IQR: <8-132.0) and median AUDIT-C was 3 (IQR: 1-6); 554 (12%) had high FIB-4. The adjusted odds ratios per 83.3 ng/mL difference in PEth and one-unit difference in AUDIT-C with high FIB-4 were 1.15 (95%CI: 1.08-1.22) and 1.03 (95%CI: 1.00-1.07), respectively. Findings were similar when PEth and AUDIT-C were treated as categorical variables. DISCUSSION: PEth was independently associated with high FIB-4, with a larger odds ratio than that of the association of AUDIT-C. The use of PEth may improve identification of alcohol use and liver fibrosis prevention and management.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk. · full record | OpenQuestion